Severin Schwan, Roche CEO (Sebastien Bozon/AFP via Getty Images)

A fail­ure in breast can­cer and now a de­lay for Po­livy? Roche can't catch a break

De­spite a sales boost last quar­ter, CEO Sev­erin Schwan not­ed sev­er­al set­backs in a pre­sen­ta­tion for in­vestors on Mon­day, in­clud­ing a de­lay in the phar­ma gi­ant’s mis­sion to bring its dif­fuse large B-cell lym­phoma (DL­B­CL) drug Po­livy to the first line.

Eight months af­ter teas­ing some pos­i­tive topline re­sults in pre­vi­ous­ly un­treat­ed pa­tients, Roche has yet to file for an ap­proval be­cause the FDA has re­quest­ed to see more da­ta on pro­gres­sion-free sur­vival, ac­cord­ing to Bill An­der­son, CEO of Roche Phar­ma­ceu­ti­cals.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.